WTX 518
Alternative Names: WTX-518Latest Information Update: 11 Apr 2024
Price :
$50 *
At a glance
- Originator Werewolf Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 18 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by Werewolf Therapeutics
- 31 Dec 2023 Werewolf Therapeutics has patent protection for IL-18 INDUKINE molecules and our WTX 518
- 31 Dec 2023 Werewolf Therapeutics announces intention to file an international application under the PCT